Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 7

1.

Safety of Sitagliptin in Patients with Type 2 Diabetes and Chronic Kidney Disease: Outcomes from TECOS.

Engel SS, Suryawanshi S, Stevens SR, Josse RG, Cornel JH, Jakuboniene N, Riefflin A, Tankova T, Wainstein J, Peterson ED, Holman RR; TECOS Study Group..

Diabetes Obes Metab. 2017 Apr 22. doi: 10.1111/dom.12983. [Epub ahead of print]

PMID:
28432745
2.

Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes.

Green JB, Bethel MA, Armstrong PW, Buse JB, Engel SS, Garg J, Josse R, Kaufman KD, Koglin J, Korn S, Lachin JM, McGuire DK, Pencina MJ, Standl E, Stein PP, Suryawanshi S, Van de Werf F, Peterson ED, Holman RR; TECOS Study Group..

N Engl J Med. 2015 Jul 16;373(3):232-42. doi: 10.1056/NEJMoa1501352. Epub 2015 Jun 8. Erratum in: N Engl J Med. 2015 Aug 6;373(6):586.

3.

Efficacy, safety and effect on biomarkers related to cholesterol and lipoprotein metabolism of rosuvastatin 10 or 20 mg plus ezetimibe 10 mg vs. simvastatin 40 or 80 mg plus ezetimibe 10 mg in high-risk patients: Results of the GRAVITY randomized study.

Ballantyne CM, Hoogeveen RC, Raya JL, Cain VA, Palmer MK, Karlson BW; GRAVITY Study Investigators..

Atherosclerosis. 2014 Jan;232(1):86-93. doi: 10.1016/j.atherosclerosis.2013.10.022. Epub 2013 Nov 1.

PMID:
24401221
4.

Skeletal muscle-derived stem cells: implications for cell-mediated therapies.

Usas A, Mačiulaitis J, Mačiulaitis R, Jakubonienė N, Milašius A, Huard J.

Medicina (Kaunas). 2011;47(9):469-79. Epub 2011 Dec 2. Review.

5.

Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial.

Home PD, Pocock SJ, Beck-Nielsen H, Curtis PS, Gomis R, Hanefeld M, Jones NP, Komajda M, McMurray JJ; RECORD Study Team..

Lancet. 2009 Jun 20;373(9681):2125-35. doi: 10.1016/S0140-6736(09)60953-3. Epub 2009 Jun 6.

PMID:
19501900
6.

Once-daily sitagliptin, a dipeptidyl peptidase-4 inhibitor, for the treatment of patients with type 2 diabetes.

Hanefeld M, Herman GA, Wu M, Mickel C, Sanchez M, Stein PP; Sitagliptin Study 014 Investigators..

Curr Med Res Opin. 2007 Jun;23(6):1329-39. Epub 2007 Apr 30.

PMID:
17559733
7.

Thyroxine vs thyroxine plus triiodothyronine in treatment of hypothyroidism after thyroidectomy for Graves' disease.

Bunevicius R, Jakuboniene N, Jurkevicius R, Cernicat J, Lasas L, Prange AJ Jr.

Endocrine. 2002 Jul;18(2):129-33. Erratum in: Endocrine. 2014 Feb;45(1):161. Jakubonien, Neli [corrected to Jakuboniene, Neli].

PMID:
12374459

Supplemental Content

Loading ...
Support Center